Literature DB >> 16386793

Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree.

Jorge Esparza-Gordillo1, Elena Goicoechea de Jorge, Cynthia Abarrategui Garrido, Luis Carreras, Margarita López-Trascasa, Pilar Sánchez-Corral, Santiago Rodríguez de Córdoba.   

Abstract

Mutations in the complement regulators factor H, membrane cofactor protein (MCP), and factor I are associated with atypical hemolytic uremic syndrome (aHUS, MIM 235400), suggesting that the disease develops as a consequence of the inefficient protection of the renal endothelium from damage by the complement system. Incomplete penetrance of the disease in individuals carrying these mutations is, however, relatively frequent. Here, we report the identification of a large, multiple affected aHUS pedigree in which there is independent segregation of three different aHUS risk factors: a MCP missense mutation (c.-598C>T; Pro165Ser) that decreases MCP expression on the cell surface, a dinucleotide insertion in the coding sequence of factor I (c.-1610insAT) that introduces a premature stop codon in the factor I protein, and the MCPggaac SNP haplotype block that was previously shown to decrease the transcription activity from the MCP promoter. Interestingly, individuals affected by aHUS in the pedigree are only those who have inherited the three aHUS risk factors. These data show an additive effect for mutations in MCP and factor I and provide definitive support to the conclusion that aHUS results from a defective protection of cellular surfaces from complement activation. Furthermore, they help to explain the incomplete penetrance of the disease, illustrating that concurrence of multiple hits in complement regulatory proteins may be necessary to significantly impair host tissue protection and to confer susceptibility to aHUS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16386793     DOI: 10.1016/j.molimm.2005.11.008

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  42 in total

1.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

2.  Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.

Authors:  Elena Bresin; Erica Rurali; Jessica Caprioli; Pilar Sanchez-Corral; Veronique Fremeaux-Bacchi; Santiago Rodriguez de Cordoba; Sheila Pinto; Timothy H J Goodship; Marta Alberti; David Ribes; Elisabetta Valoti; Giuseppe Remuzzi; Marina Noris
Journal:  J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 10.121

3.  Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome.

Authors:  M Kathryn Liszewski; Marilyn K Leung; Barbara Schraml; Timothy H J Goodship; John P Atkinson
Journal:  Mol Immunol       Date:  2006-10-05       Impact factor: 4.407

4.  Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population.

Authors:  R Martínez-Barricarte; E Goicoechea de Jorge; T Montes; A G Layana; S Rodríguez de Córdoba
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

Review 5.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

Review 6.  Advances and challenges in the management of complement-mediated thrombotic microangiopathies.

Authors:  Jean-Claude Davin; Nicole C A J van de Kar
Journal:  Ther Adv Hematol       Date:  2015-08

Review 7.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

Review 8.  Genetics and complement in atypical HUS.

Authors:  David Kavanagh; Tim Goodship
Journal:  Pediatr Nephrol       Date:  2010-06-06       Impact factor: 3.714

9.  Shiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice.

Authors:  D Paixão-Cavalcante; M Botto; H T Cook; M C Pickering
Journal:  Clin Exp Immunol       Date:  2009-02       Impact factor: 4.330

Review 10.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.